Long-term use of benzodiazepines: Tolerance, dependence and clinical problems in anxiety and mood disorders

Pharmacopsychiatry

Volumn 29, Issue 4, 1996, Pages 127-134

  Michelini, S ^a   Cassano, G B ^a   Frare, F ^a   Perugi, Giulio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PHENOBARBITAL; ZACOPRIDE;

AMNESIA; ANXIETY; CLINICAL FEATURE; DEPRESSION; DRUG DEPENDENCE; DRUG TOLERANCE; HUMAN; MOOD; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

EID: 0030036620     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979558     Document Type: Review

References (93)

1. American Psychiatric Association: Benzodiazepine dependence, toxicity, and abuse. A task force reports of the American Psychiatric Associaton. American Psychiatric Associaton, Washington, D.C., 1990
2. Aranko, K., M. J. Mattila, T. Seppala: Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br. J. Clin. Pharmacol. 15 (1983) 542-552
3. Ayd, F. J.: Benzodiazepine dependence and withdrawal. J. Psychoact. Drugs 15 (1983) 67
4. Balmer, R., R. Battegay, R. von Marchall: Long-term treatment with diazepam: investigation of consumption habits and interaction between psychotherapy and psychopharmacotherapy: a prospective study. Pharmacopsychiatry 16 (1981) 221-234
5. Balter, M. B., D. I. Manheimer, G. D. Mellinger, E. H. Uhlenhuth: A crossnational comparison of antianxiety/sedative drug use. Curr. Med. Res. Opin. 8 (1984) 5-20
6. Bassi, S., M. G. Albizzati, C. Ferrarese, L. Frattola, B. Cesana, R. Piolti, A. Farolfi: Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients. Clinical Neuropharmacology 12 (1989) 67-74
7. Burrows, G. D., T. R. Norman, F. K. Judd, P. F. Marriott.: Short-acting vs long-acting benzodiazepine discontinuation effects in panic disorders. J. Psychiatric Res. (Suppl.) 2 (1990) 65-72
8. Busto, U., E. M. Sellers, C. A. Naranjo et al: Withdrawal reaction after long term therapeutic use of benzodiazepines. New Engl. J. Med. 315 (1986) 854-859
9. Byrnes, J. J., L. G. Miller, K. Perkins, D. J. Greenblatt, R. I. Shader: Chronic benzodiazepine administration XI: concurrent administration of PK11195 attenuates lorazepam discontinuation effects. Neuropsychopharmacology 8 (1993) 267-273
10. Christensen, J. D.: Tolerance development with chorazepoxide in relation to the plasma level of parent compound and its main metabolites in mice. Acta Pharmacologica et Toxicologica 33 (1973) 262-272
11. Cole, J. O., R. J. Chiarello: The benzodiazepine as drug of abuse. J. Psychiat. Res. 24 (1990) 135-144
12. Concas, A., M. Serra, M. Salis, V. Nurchi, G. Crisponi, G. Biggio: Evidence for an envolvement of GABA receptors in the mediation of the proconvulsant action of ethyl-beta-carboline-3-carboxylate. Neuropharmacol. 23 (1984) 323-326
13. Crawley, J. N., P. J. Marangos, J. Stivers: Cronic clonazepam administration induces benzodiazepine receptors subsensitivity. Neuropharmacology 92 (1987) 358-364
14. DuPont, R. L.: A practical approach to benzodiazepine discontinuation. J. Psych. Res. 24 (1990) 81-90
15. Emmett-Oglesby, M. W., D. A. Lytle, S. A. English: Abecarnil used to treat benzodiazepine withdrawal. Psychopharmacol. Ser. 11 (1993) 121-131
16. Fabre, L. F., D. M. McLemond, A. G. Stephens: Comparison of the therapeutic effect, tolerance, and safety of ketazolam and diazepam administered for six months to outpatients with cronic anxiety neurosis. J. Int. Med. Res. 9 (1981) 191-198
17. File, S. E., N. Andrews: Benzodiazepine withdrawal: behavioral pharmacology and neurochemical changes. Biochem. Soc. Symp. 59 (1993) 97-106
18. File, S. E.: Recovery from lorazepam tolerance and the effect of a benzodiazepine antagonist (RO 15-1788) on the development of tolerance. Psychopharmacology 77 (1982) 284-288
19. Fontaine, R., G. Chominard, L. Annable: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepines treatment. Am. J. Psychiatry 141 (1984) 848-852
20. Fyrer, A. J., M. R. Liebowitz, J. M. Gorman: Discontinuation of alprazolam treatment in panic patients. Am. J. Psychiatry 144 (1987) 303-308
21. Gallager, D. W., C. Heninger, M. A. Wilson: Chronic BDZ agonist exposure and its consequences for GABA-BDZ interactions. In: Allosteric modulation of amino acid receptors: therapeutic implications. Barnard, E. A. and E. Costa (ed.), Raven Press, New York (1989) 91-108
22. Gallager, D. W., J. M. Lakoski, S. F. Gonsalves, S. L. Rauch: Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308 (1984) 74-77
23. Gallager, D. W., M. A. Wilson: Chronic BDZ agonist exposure: comparison of electrophysiological changes by brain region and BDZ receptor ligand. In: Chloride channels and their modulation by neurotransmitters and drugs. Biggio, G. and E. Costa (ed.), Raven Press, New York (1988) 325-336
24. Gardner, C. R., R. Deacon, G. Mann, P. Budhram, A. P. Guy: Agonist and antagonist effects of RU 32514, a new non-benzodiazepine receptor ligand for benzodiazepine receptors. Br. J. of Pharmac. 92 (1987a) 655
25. Gardner, C. R., R. Deacon, G. Mann, P. Budhram, P. Miller: RU 32698, a new benzodiazepine receptor ligand with anxiolytic but little sedative/myorelaxant properties. Br. J. of Pharmac. 92 (1987b) 537
26. Garvey, M. J., G. D. Tollefson: Prevalence of misuse of prescribed benzodiazepines in patients with primary anxiety disorder or major depression. Am. J. Psychiatry 143 (1986) 1601-1603
27. Gonsalves, S. F., D. W. Gallager: Time course for development of anticonvulsivant tolerance. Brain Res. 405 (1987) 94-99
28. Goodman, W. K., D. S. Charney, L. H. Price, S. W. Woods, Heninger: Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am. J. of Psychiatry 143 (1986) 900
29. Gorenstein, C., M. A. Bernik, S. Pompeia: Differential acute psychomotor and cognitive effects on diazepam on long-term benzodiazepine users. Int. Clin. Psychopharmacol. 9 (1994) 145-153
30. Greemblatt, D. J., L. G. Miller, R. I. Shader: Benzodiazepine discontinuation syndromes. J. Psych. Res. 24 (1990) 73-79
31. Greenblatt, D. J., R. I. Shader: Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab. Rev. 8 (1978) 13-28
32. Haefeley, W.: Pharmacology of partial agonists at the benzodiazepine receptors. In: Biological Psychiatry. Racagni, G., N. Brunello, T. Fukuda (ed.), Excerpta Medica, Amsterdam, vol.1 (1991) 705-707
33. Haefely, W., J. R. Martin, P. Schoch: Novel anxiolytic that act as partial agonist at benzodiazepine receptors. Trends Pharmacol. Sci. 11 (1990) 452-456
34. Haigh, J. R. M., M. Feeley: Tolerance to the anticonvulsant effect of benzodiazepine. Trends in Pharmacologic Sciences 9 (1988) 361-366
35. Hellerstein, D. J., D. M. Flansaas, L. D. Zweben-Howland, L. W. Samstag: A clinical profile of patients affected by a state regulation of benzodiazepine prescriptions. Hosp. Community Psychiatry 45 (1994) 362-365
36. Hollister, L. E.: Pharmacology and pharmacokinetics of the minor tranquilizers. Psychiatr. Ann. (Suppl.) 2 (1981) 26-31
37. Hu, X. J., M. K. Ticku: Chronic flurazepam treatment produces decreased efficacy of the benzodiazepine ligands and pentobarbital with gamma-aminobutyric acid-A receptors in cortical neurons. J. Pharmacol. Exp. Then 270 (1994) 485-490
38. Jenk, F., J. L. Moreau, E. P. Bonetti, J. R. Martin, W. E. Haefely: Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J. Pharmacol. Exp. Ther. 262 (1992) 1121-1127
39. Kales, A., R. L. Manfredi, A. N. Vgontzas, E. O. Bixler, A. Vela-Bueno, E. C. Fee: Rebound insomnia after only brief and intermittment use of rapidly eliminated benzodiazepines. Clin. Pharmacol. Then 49 (1991) 468-476
40. Kleber, H. D.: The nosology of abuse and dependence. J. Psych. Res. 24 (1990) 57-64
41. Krause, W., F. Reibmann, W. Schunack, Chr. Schobel: Comparative pharmacokinetics of abecarnil in rat following single and multiple intragastric treatment and continous administration via the diet. Drug metabolism and disposition 19 (1991) 29-35
42. Lader, M., I. Farr, S. Morton: A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. Int. Clin. Psychopharmacol. 8 (1993) 31-36
43. Lader, M.: Benzodiazepine withdrawal. In: Handbook of anxiety. Noyes, R., M. Roth, G. D. Burrows (ed.), Elsevier, Amsterdam, Vol. 4 (1990) 57-71
44. Lader, M. H.: Low dose therapeutic benzodiazepine dependence: are there differences between benzodiazepines? In: Biological Psychiatry. Racagni, G., N. Brunello, T. Fukuda (ed.), Excerpta Medica, Amsterdam, Vol.1 (1991) 775-777
45. Lader, M. L.: Psychopharmacology of benzodiazepines. J. Psych. Res. 44 supp. 2 (1990) 33-34
46. Little, H. J., D. J. Nutt, S. C. Taylor: Selective changes in the in vivo effects of benzodiazepine receptor ligands after chemical kindling with FG 7142. Neuropharmacol. 26 (1987) 25-31
47. Little, H.: Chronic BDZ treatment increases the effect of the inverse agonists. In: Chloride channels and their modulation by neurotransmitters and drugs. Biggio, G. and E. Costa (ed.), Raven Press, New York (1988) 307-323
48. Little, H. J., D. J. Nutt, S. C. Taylor: Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. Brain Res. Bull. 19 (1987a) 371-378
49. Little, H. J., D. J. Nutt, S. C. Taylor: Kindling and withdrawal changes at the benzodiazepine receptor. J. Psychopharmacol. 1 (1987b) 35-46
50. Little, H. J., R. Gale, N. Sellars, D. J. Nutt, S. C. Taylor: Chronic benzodiazepine treatment increases the effects of the inverse agonist FG 7142. Neuropharmacology 27 (1988) 383-389
51. Lucki, I., K. Rickels, A. M. Geller: Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 89 (1986) 555-558
52. Marks, J.: The benzodiazepines, use, overuse, misuse, abuse. MTP Press, Lancaster (1978)
53. Marriot, S., P. Tyrer: Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf. 9 (1993) 93-103
54. Martinez, J. A., M. J. Fargeas, L. Bueno: Physical dependence on diazepam: precipitation of abstinence syndromes by peripheral and central benzodiazepine receptor antagonists. Pharmacol. Biochem. Behav. 41 (1992) 461-464
55. Mellinger, G. D., M. B Balter, E. H. Uhlenhuth: Prevalence and correlates of the long-term regular use of anxiolytics. J.A.M.A. 251 (1984) 375-379
56. Miller, L .G., W. Galpern, M. Lumpkin, J. Heller, D. J. Greenblatt, R. I. Shader: Chronic administration of the benzodiazepine partial agonist Ro 16-6028 does not produce tolerance or receptor alterations. Clinical Pharmac. and Therap. 47 (1990) 135
57. Miller, L. G., W. R. Galpern, D. J. Greenblatt, M. Lumpkin, R. I. Shader: Chronic benzodiazepine administration. IV. A partial agonist produces behavioral effects without tolerance or receptors alterations. The J. of Pharm. and Exp. Therap. 254 (1990) 33-38
58. Miller, L. G.: Chronic benzodiazepine administration: from the patient to the gene. J. Clin. Pharmacol. 31 (1991) 492-495
59. Morishira, H., K. Kushiku, J. Matsuki, T. Tokunaga, T. Inoue, R. Mori, H. Kawamoto, T. Furukuwa: Pharmacological effects of the anti-anxiety compound suriclone and its principal metabolites. Drug Res. 37 (1987) 1332-1340
60. Morrow, A. L., P. D. Suzdak, S. M. Paul: Benzodiazepine, barbiturate, ethanol, and hypnotic steroid hormone modulation of GABA-mediated chloride ione transport in rat brain synaptoneurosomes. In: Chloride channels and their modulation by neurotransmitters and drugs. Biggio, G. and E. Costa (ed.), Raven Press, New York (1988) 247-261
61. Neppe, V. M., J. Sindorf: Carbamazepine for high-dose diazepam withdrawal in oppiate users. J. Nerv. Ment. Dis. 179 (1991) 234-235
62. Noyes, R., M. J. Garvey, B. L. Cook, P. J. Perry: Benzodiazepine withdrawal: a review of the evidence. J. Clin. Psychiatry 49 (1988) 382-389
63. Nutt, D. J.: Benzodiazepine dependence in the clinic: reason for anxiety. Trends Pharmacol. Sci. 7 (1986) 457-460
64. Nurr, D. J.: Pharmacological mechanisms of benzodiazepine withdrawal. J. Psych. Res. 24 (1990) 105-110
65. Olsen, R. W., A. J. Tobin: Molecular biology of GABA-A receptors. The Faseb J. 4 (1990) 1469-1480
66. Otto, M. W., M. H. Pollak, S. Meltzer-Brody, J. F. Rosenbaum: Cognitive-behavioral therapy for benzodiazepine discontinuation in panic disorder patients. Psychopharmacol. Bull. 28 (1992) 123-130
67. Owen, R. T., P. Tyrer: Benzodiazepine dependence. Drugs 25 (1983) 385
68. Pecknold, J. C., R. P. Swinson, K. Kuch, C. Lewis: Alprazolam in panic disorder and agoraphobia. Results from a multicenter trial discontinuation effects. Archives of General Psychiatry 45 (1988) 429-436
69. Petturson, H., M. H. Lader: Withdrawal from long-term benzodiazepine treatment. Br. Med. J. 283 (1991) 643-645
70. Piot, O., J. Betschart, J. M. Stutzmann, J. C. Blanchard: Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice. Neurosc. Lett. 117 (1990) 140-143
71. Power, K. G., D. W. A. Jerrom, R. J. Simpson, M. Mitchell: Controlled study of withdrawal symptoms and rebound anxiety after six week course of diazepam for generalized anxiety. Brit. Med. J. 290 (1985) 1246-1248
72. Rickels, K., E. Schweitzer, W. G. Case, D. Greenblatt: Long-term therapeutic use of benzodiazepines. I Effects of abrupt discontinuation. Arch. Gen. Psychiatry 47 (1990) 899-907
73. Rickels, K., W. G. Case, E. Schweitzer, C. Swanson, R. B. Fridman: Low dose dependence in chronic benzodiazepine users: a preliminary report in 119 patients. Psychopharmacol. 22 (1986) 407-415
74. Rickels, K., W. G. Case, E. Schweitzer: Management of benzodiazepines discontinuation. In: Biological Psychiatry. Racagni, G., N. Brunello, T. Fukuda (ed.), Excerpta Medica, Amsterdam, Vol. 1 (1991) 778-779
75. Rickels, K.: Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch. Gen. Psychiatry 45 (1988) 444-450
76. Roy-Byrne, P. P., M. D. Sullivan, D. S. Cowley, R. K. Ries: Adjunctive treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J. Psychiatr. Res. Suppl. 1 (1993) 143-153
77. Royal College of Psychiatrists: Benzodiazepine and dependence: a College statement. Bull. R. Coll. Psychiatrists 12 (1988) 107
78. Salzman, C.: Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J. Psychiatr. Res. Suppl. 1 (1993) 97-110
79. Sauvanet, J. P., S. Z. Langer, P. L. Morselli: Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. Raven Press, New York (1988)
80. Schoch, P., J. L. Moreau, J. R. Martin, W. E. Haefely: Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. Biochem. Soc. Symp. 59 (1993) 121-134
81. Schweitzer, E., K. Rickels, W. G. Case, D. J. Greenblatt: Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch. Gen. Psychiatry 48 (1991) 448-452
82. Schweitzer, E., K. Rickels, W. G. Case, D. Greenblatt: Long-term therapeutic use of benzodiazepines. II Effect of gradual taper. Arch. Gen. Psychiatry 47 (1990) 908-915
83. Schweitzer, E., K. Rickels: Failure of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Am. J. of Psychiatry 143 (1986) 1590
84. Sellers, E. M., U. Busto, H. C. Kaplan: Clinical abuse of partial and full agonist benzodiazepines. In: Biological Psychiatry. Racagni, G., N. Brunello, T. Fukuda (ed.), Excerpta Medica, Amsterdam, Vol. 1 (1991) 709-710
85. Sheehan, D.: Benzodiazepines in panic disorders and agoraphobia. J. Affect. Disord. 13 (1987) 169-181
86. Smith, D. E., M. J. Landry: Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polidrug abuse. J. Psych. Res. 24 (1990) 145-156
87. Stephens, D. N., H. H. Schneider, R. Weidmann, L. Zimmermann: Decreased sensitivity to BDZ receptor agonists and increased sensitivity to inverse agonist following chronic treatments: evidence for separate mechanisms. In: Chloride channels and their modulation by neurotransmitters and drugs. Biggio, G. and E. Costa (ed.), Raven Press, New York (1988) 337-354
88. Swantek, S. S., G. T. Grossberg, V. M. Neppe, W. C. Doubek, T. Martin, J. E. Bender: The use of carbamazepine to treat benzodiazepine withdrawal in a geriatric population. J. Geriatr. Psychiatry Neurol. 4 (1991) 106-115
89. Tata, P. R., J. Rollings, M. Collins, A. Pickering, R. R. Jacobson: Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol. Med. 24 (1994) 203-213
90. Tricklebank, M. D., T. Honoré, S. D. Iversen, J. A. Kemp, A. R. Knight, G. R. Marshall, N. M. J. Rupniak, L Singh, S. Tye, F. Watjen, E. H. F. Wang: The pharmacological properties of the imidazobenzodiazepine, FG 8205, a novel partial agonist at the benzodiazepine receptors. Br. J. of Pharmac. 101 (1990) 753-761
91. Tyrer, R., D. Rutherford, T. Huggett: Benzodiazepine withdrawal symptoms and propranolol. Lancet 1 (1981) 520-522
92. Wilson, M. A., C. Heninger, D. W. Gallager: Response to various BDZ receptor ligands following chronic diazepam exposure in rats: SN reticulata sensitivity and GABA modification of receptor binding. Soc. Neurosci. Abst. 13 (1987) 962
93. Woods, J. H., J. L. Katz, G. Winger: Abuse liability of benzodiazepine. Pharmacological reviews 39 (1987) 251-419